                </a></li></ul></div><p><strong>Figure 3.  <span>TLR ligands preferentially activate CD4+ central memory and effector memory T cells and CD8+ effector memory T cells.</span></strong></p><a id="article1.body1.sec2.sec2.fig2.caption1.p1" name="article1.body1.sec2.sec2.fig2.caption1.p1"></a><p>Intracellular Ki-67 expression (3A, 3C) and cell surface CD69 (3B, 3D) were analyzed after 7 days' incubation of PBMC in medium alone, or in medium supplemented with plate bound anti-CD3 antibodies, or the indicated TLR ligand. <a href="#pone-0001915-g003">Figures 3A and B</a> are representative results among phenotypically defined naïve (CD45RA<sup>+</sup>CD45RO<sup>−</sup>CCR7<sup>+</sup>), central memory (CD45RA<sup>−</sup>CD45RO<sup>+</sup>CCR7<sup>+</sup>), and effector memory (CD45RA<sup>−</sup>CD45RO<sup>+</sup>CCR7<sup>−</sup>) CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Values represent percentages of cells staining for Ki-67 or CD69. <a href="#pone-0001915-g003">Figures 3C and 3D</a> reflect the mean data from 15 separate experiments. Values nominally significantly different from medium alone values (Wilcoxon Sign Rank Test) are shown with an asterisk.</p>
